University of Texas, Houston
Welcome,         Profile    Billing    Logout  
 17 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mayes, Maureen D
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2/3
301
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen, Horizon Therapeutics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/25
09/25
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
NCT05626751 / 2021-006271-42: An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Enrolling by invitation
2
240
Europe, Japan, US, RoW
HZN-825
Amgen, Horizon Therapeutics USA, Inc, Horizon Therapeuthics USA, Inc
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
09/26
09/26
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Feldman, Robert M
NCT04362241: DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Recruiting
4
30
US
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE], Prednisolone Acetate 1%
Ophthalmic Consultants of the Capital Region
Retinopathy, Diabetic
02/22
03/22
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Recruiting
1
42
US
OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212
Olix Pharmaceuticals, Inc., Trial Runners, LLC
Neovascular Age-related Macular Degeneration
11/24
12/24
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
Pearson, Deborah A
NCT02649959: An Open Label Study of CM-AT for the Treatment of Children With Autism

Active, not recruiting
3
405
US
CM-AT
Curemark
Autism
01/25
01/25
Lopez, George
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
ESCAPE-MeVO, NCT05151172: EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions ( Trial)

Active, not recruiting
N/A
530
Europe, Canada, US
endovascular thrombectomy (EVT), solitaire X, Standarad medical care
Dr. Michael D Hill, University of Calgary
Acute Ischemic Stroke
12/25
06/26
Patel, Bela
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
PE-TRACT, NCT05591118: Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Recruiting
3
500
US
Anticoagulant Therapy, Catheter-Directed Therapy
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Embolism
01/27
01/28
NECTAR, NCT04924660: Novel Experimental COVID-19 Therapies Affecting Host Response

Completed
2/3
871
US
TXA127, TRV027, Placebo, Fostamatinib
Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
10/23
12/23
NCT04482595: BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

Active, not recruiting
2
50
US
BIO 300 Oral Suspension, Placebo
Humanetics Corporation, NYU Langone Health, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
07/24
04/25
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
07/25
07/25
Eichenwald, Eric C
NCT01353313: Hydrocortisone for BPD

Active, not recruiting
3
800
US
Hydrocortisone, Placebo
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS)
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
09/20
01/25
MoCHA, NCT03340727: Moderately Preterm Infants With Caffeine at Home for Apnea () Trial

Terminated
3
827
US
Caffeine Citrate, Placebo
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Apnea of Prematurity
01/23
03/23
BiB, NCT04545866: The Budesonide in Babies () Trial

Active, not recruiting
3
1160
US
budesonide (Pulmicort nebulizing suspension)., Pulmicort nebulizing suspension., surfactant (poractant alfa;Curosurf), poractant alfa;Curosurf
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
09/24
12/26
NCT03456336: Management of the PDA Trial

Active, not recruiting
3
836
US
Active Treatment, Expectant Management
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Premature, Patent Ductus Arteriosus, Infant, Newborn, Diseases, Patent Ductus Arteriosus After Premature Birth
04/25
05/27
NCT03321734: Intermittent Hypoxia and Caffeine in Infants Born Preterm

Completed
2
170
US
Caffeine, Placebos
Children's National Research Institute, Boston University, Beth Israel Medical Center, University of Massachusetts, Worcester, American SIDS Institute, Walter Reed National Military Medical Center, Dartmouth-Hitchcock Medical Center, Children's Hospital of Philadelphia, Johns Hopkins All Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Intermittent Hypoxia
06/23
06/23
NCT03927833: Cycled Phototherapy

Recruiting
N/A
1700
US
Phototherapy lights
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyper Bilirubinemia, Premature Infant
07/25
07/25
NCT00063063: Generic Database of Very Low Birth Weight Infants

Recruiting
N/A
80000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
NCT00009633: Follow-up Visit of High Risk Infants

Recruiting
N/A
68000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
Carpenter, Shawnee
NCT02960555: Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Active, not recruiting
2
61
US
Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
04/25
04/30
Kershaw, Kiarri
ASPIRIN, NCT06468202: Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: TRIAL

Recruiting
4
10742
US
Aspirin 81 mg, Aspirin 162 mg
Ohio State University, Patient-Centered Outcomes Research Institute, Northwestern University, Preeclampsia Foundation
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
01/29
02/30
Araji, Sarah
ASPIRIN, NCT06468202: Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: TRIAL

Recruiting
4
10742
US
Aspirin 81 mg, Aspirin 162 mg
Ohio State University, Patient-Centered Outcomes Research Institute, Northwestern University, Preeclampsia Foundation
Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
01/29
02/30

Download Options